Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yep..
ur momma.. lol
yes sir..I do
Without u we r incomplete..
Please fasten ur seatbelts and place ur tray in the upright position......
SQNM almost traded float/0S.. up from here IMO
Almost traded the float and OS...
Outstanding Float
60,675,573 59,953,027
Its seems the Flordia boys r kicking ass lately..
nice@!!!!!!!!!!!!!!!!!!!
yep...lol minus 55 cents..
THC looking great bro..
Cool I hope my brothers r making money!!!!
Oh Forgot sisters too..
SRZ up 29%
go SQNM>>>>>>>>
SRZ up 15%
SRZ up 5% in Pre
I am fishing.. Hoping to catch them like u and Dom..
I will be looking in the am
exactly.. Only panic.. emotions rule the market. I am just confused not alot of buying AH
Here is the reason the stock went up in 2008.. So I think its safe to say people freaked and assumed the worse..
Sequenom has its sights on developing more than just the first non-invasive prenatal test for Down syndrome. Today, scientists affiliated with the San Diego-based biotech company are reporting how their methods of analyzing genes in a sample of blood from the mother can be used to detect whether a developing fetus has a single-gene defect, like cystic fibrosis, or inherited blood diseases like beta-thalassemia and sickle-cell anemia.
Researchers led by Dennis Lo, a professor at the Chinese University of Hong Kong, have shown that by using digital PCR technology, they can count abnormal gene sequences in samples of a mother’s blood that can determine whether an unborn fetus has an inherited disease. The findings are being reported online today in the Proceedings of the National Academy of Sciences.
The findings could potentially eliminate the need for more invasive tests used to spot such defects, like amniocentesis or CVS, which raise the risk of miscarriage. The technology developed by Lo and his colleagues is licensed exclusively to Sequenom (NASDAQ: SQNM), and is also used to screen a mother’s blood sample for evidence of Down syndrome. The test for Down’s was found in September to be 100 percent accurate in a study of 400 women, which sent Sequenom shares soaring more than 35 percent. The market for prenatal chromosomal disorders like Down’s could be worth $3 billion to $5 billion worldwide, and the business opportunity could be even larger when applied to tiny variations in genetic code that cause cystic fibrosis, heart ailments, and other birth defects, Sequenom CEO Harry Stylli said earlier this month at an investor conference.
“Sequenom is committed to developing the next-generation of prenatal diagnostic tools that will provide physicians with the capabilities they need to noninvasively diagnose genetic disorders early in a woman’s pregnancy,” Stylli said in a statement. “Dr. Lo and his team have made another important breakthrough in prenatal diagnostics with these findings. These unique, noninvasive digital technologies have the potential to dramatically impact the prenatal diagnostic market.”
Through using the “digital counting” method that looked for single-gene abnormalities in maternal blood, the scientists were able to diagnose beta-thalassemia and hemoglobin E disease—types of anemia that affect millions of people worldwide. About 10,000 different human diseases are thought to be caused by single-gene defects, Sequenom said.
Sequenom had planned to launch its genetic test, called SEQureDx, in June. In a statement released after the market closed, Sequenom described the delayed launch as a “temporary setback” and said the SEQureDx technology “is scientifically and technically sound.” SEQureDx is intended to test a pregnant mother’s blood sample.
But the company did not explain how research and development data for SEQureDx was mishandled. “All I can really say is that during a management review of the data we discovered inconsistencies, which led to the discovery of mishandling of data,” Sequenom spokesman Ian Clements said late today.
The disclosure prompted the board to form a special committee of independent directors to oversee an investigation “of the employees’ activity related to the test data and results.” Sequenom said the incident also has prompted a review of data supporting its Cystic Fibrosis, Fetalxy, and Rhesus D tests, which Clements said also is expected to push back the release of those tests. “We don’t currently believe that data is affected, but we don’t want to take any risks,” Clements said. As a result, those tests are now anticipated to begin launching in the third quarter of this year.
Sequenom said the questioned data has not changed its plans for using parallel RNA- and DNA-based methods to test for Down syndrome, and the company will endeavor to have a validated test completed by the end of this year.
not sure.. they r investigating what happen with the r&d.
crazy that no one is really buying in ah??
Nothing but panic. But could be good for us
SEQUENOM Reports First Quarter 2009 Financial Results
On Wednesday April 29, 2009, 4:40 pm EDT
Sequenom Inc.
SAN DIEGO--(BUSINESS WIRE)--SEQUENOM, Inc. (NASDAQ: SQNM - News) today reported its financial results for the quarter ended March 31, 2009.
SEQUENOM reported first quarter 2009 revenues of $8.7 million, compared with revenues of $10.6 million reported for the first quarter of 2008. The decrease in revenues for the first quarter was primarily due to a decrease in system sales and services in the company’s genetic analysis business. Net loss for the first quarter of 2009 was $17.5 million, or $0.29 per share, compared with $8.6 million, or $0.19 per share, for the first quarter of 2008. The increase in net loss during the first quarter of 2009, compared with the first quarter of 2008, reflects increased general and administrative expenses and expenses associated with the planned launch of various noninvasive prenatal tests.
System revenues were $2.4 million, as compared to $3.7 million in the prior period while consumable sales rose modestly (1.3%) to $4.7 million. Gross margin was 61% for the first quarter of 2009, compared with 56% for the first quarter of 2008. The increased gross margin was attributable to higher relative sales in consumables (which have higher gross margins), as compared to lower relative system and contract research revenues (which traditionally have lower gross margins).
Research and development expenses were $8.8 million for the first quarter of 2009, compared with $4.9 million for the same period of 2008. The increase in research and development expenses for the first quarter of 2009 reflected additional expenses associated with the company’s investment in its molecular diagnostic technology and product development, increased clinical study costs and increased headcount-related expenses (including higher stock-based compensation expense), primarily associated with the building of the company’s infrastructure for its molecular diagnostics business. Selling, general and administrative expenses for the first quarter of 2009 were $14.3 million compared with $9.2 million for the first quarter 2008. The increase in selling, general and administrative expenses in 2009 resulted from increased headcount-related expenses related to the building of the company’s diagnostics sales force, as well as legal fees associated with on-going litigation and acquisition activities. Total operating expenses for the first quarter of 2009 were $23 million, compared with $14.1 million for the first quarter of 2008.
As of March 31, 2009 SEQUENOM had total cash and short- and long-term marketable securities of $87 million and $7.8 million in accounts receivable.
Updated 2009 Financial Guidance
SEQUENOM is updating its 2009 financial guidance as follows:
Genetic Analysis:
The company anticipates 2009 revenues to range between $32 million and $35 million
Gross margin is expected to be approximately 57% in 2009
After corporate allocations Genetic Analysis is expected to report a loss of between $10 million to $12 million, which includes approximately $5 million in non-cash FAS 123R expense, while incurring a cash burn after corporate allocations of breakeven to $2.0 million.
Molecular Diagnostics
The company is not providing revenue guidance for the molecular diagnostic business. However, Molecular Diagnostics is expected to incur a net loss after corporate allocations of between $52 million to $55 million, which includes approximately $7 million in non-cash FAS 123R expense, while incurring a cash burn after corporate allocations of approximately $45 million to $50 million.
Consolidated
On a consolidated basis the company is expected to report a 2009 loss of between $62 million to $67 million, which includes approximately $12 million in non-cash FAS 123R expenses.
On a consolidated basis, the company is expected to have a cash burn of between $45 million to $52 million.
Conference Call
Due to the news announced earlier today SEQUENOM’s management is rescheduling the earnings call previously scheduled for Thursday, April 30 to today at 2:00 p.m. Pacific time. Individuals interested in participating in the conference call may do so by dialing (866) 844-2998 for domestic callers or (706) 679-9912 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the investor relations section of the company’s website at www.sequenom.com.
A webcast replay will be available on the SEQUENOM Web site for 14 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 93862699
UPDATE 1-Sequenom delays Down syndrome test; shares tank !
Says delays launch of Down syndrome test
* Cites employee mishandling
* Shares fall over 60 percent
April 29 (Reuters) - Sequenom Inc (SQNM.O) said employee mishandling of R&D test data and results has forced it to delay the launch of a Down syndrome test, sending its share plunging more than 60 percent after the bell.
The maker of genetic analysis products said it is no longer relying on previously announced research and development test data and results related to its SEQureDx technology.
The company said its board has formed a special committee of independent directors to oversee an independent investigation of the employees' activity related to the test data and results.
However, Sequenom also said its SEQureDx technology remained scientifically and technically sound, and that it would endeavor to have a validated test in the fourth quarter of 2009.
Separately, the San Diego-based company forecast 2009 revenues in the range of $32 million and $35 million, compared with the Wall Street consensus of $55.2 million.
In heavy trading after the bell, Sequenom shares were down to $4.75. They closed at $14.91 Wednesday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Anthony Kurian)
Exactly. Captain I will dig also and hit u and the board up with the any info..
I guess the words "mishandling test data"!!! Did it..
How would u like to have own SQNM shares at closing?
We need to radar this.
SQNM 14.91 down after hours to 4.60 should be interesting..
Sequenom 1Q loss widens on costs
Forbes - 21 minutes ago
Sequenom's expenses rose 41 percent to $26.5 million, mainly on research and development costs. Meanwhile, consumable revenue ...SEQUENOM Announces Delay in launch of sequredx Trisomy 21 Test.
Sequenom Drops In After-Hours On Test Delay Trading Markets
Sequenom Shares Tumble After Worker ‘Mishandling' of Test Data
Jackson do they have a court day set or pre trial date for JPM yet?
Bigz your thoughts on coin now?
I don't want to be incorrect with my statement but aren't u mostly in preferred??
Your definitely asking the right person he has been around along time and knows alot about it...
yes it is nice to be green......
WAMUQ looking great...
2.41
My girl gave me a bitch slappin due to r mascott. lol